Abstract:
Borosilicate glasses, preferably for use in the pharmaceutical sector, are provided. The borosilicate glasses are outstandingly suitable for the use as pharmaceutical primary packaging, such as phials or ampoules, since the aqueous or water-containing medicaments kept in the containers do not attack the glass significantly, and so the glass releases no, or only few, ions. The borosilicate glasses have the following composition in % by weight or consist thereof: SiO271-77; B2O39-12; Al2O35.5-8; Na2O6-8; K2O0.1-0.9; Li2O0-0.3; CaO0-1.5; BaO0-1; F0-0.3; Cl-0-0.3; and MgO + CaO + BaO + SrO 0-2.
Abstract:
An optical converter for producing colored or white light from blue excitation light is provided. The converter has good scattering properties to be able to produce nearly white light from the scattered blue light components and the scattered, converted yellow light components. The optical converter includes material including one or more of a YAG ceramic, a LuAG ceramic, and a magnesium-aluminum ceramic exhibiting strong scattering.
Abstract:
A conversion material for a white or colored light source is provided. The material includes a matrix glass that, as bulk material, for a thickness of about 1 mm, has a pure transmission of greater than 80% in the wavelength region from 350 to 800 nm and in the region in which the primary light source emits light, wherein the sum of transmission and reflection of the sintered matrix glass without luminophore is at least greater than 80% in the spectral region from 350 nm to 800 nm and in the spectral region in which the primary light source emits light.
Abstract:
Borosilicate glasses, preferably for use in the pharmaceutical sector, are provided. The borosilicate glasses are outstandingly suitable for the use as pharmaceutical primary packaging, such as phials or ampoules, since the aqueous or water-containing medicaments kept in the containers do not attack the glass significantly, and so the glass releases no, or only few, ions. The borosilicate glasses have the following composition in % by weight or consist thereof: SiO271-77; B2O39-12; Al2O35.5-8; Na2O6-8; K2O0.1-0.9; Li2O0-0.3; CaO0-1.5; BaO0-1; F0-0.3; Cl-0-0.3; and MgO + CaO + BaO + SrO 0-2.
Abstract translation:提供优选用于制药领域的硼硅酸盐玻璃。 硼硅酸盐玻璃非常适合用作药物初级包装,例如药瓶或安瓿,因为保持在容器中的含水或含水药物不会显着地侵蚀玻璃,因此玻璃不会释放出或仅少量的, 离子。 硼硅酸盐玻璃具有以重量%计的以下组成或其组成:SiO 2 71-77; B2O3 9-12; Al2O3 5.5-8; Na2O 6-8; K2O 0.1-0.9; Li2O 0-0.3; CaO 0-1.5; BaO 0-1; F 0-0.3; Cl- 0-0.3; 和MgO + CaO + BaO + SrO 0-2。
Abstract:
A pharmaceutical packaging is provided including a glass, comprising at least the following components (given in mol % on oxide basis): SiO2: 5 9-84, Al2O3: 7-18.5, CaO: 1-25, SrO: 0-6.5, BaO: 0-5, ZrO2: 0-3, TiO2: 0-5, B2O3: 0-1, wherein the ratio (CaO+SrO+BaO)/Al2O3
Abstract:
An optical converter for producing colored or white light from blue excitation light is provided. The converter has good scattering properties to be able to produce nearly white light from the scattered blue light components and the scattered, converted yellow light components. The optical converter includes material including one or more of a YAG ceramic, a LuAG ceramic, and a magnesium-aluminum ceramic exhibiting strong scattering.
Abstract:
An imaging system, includes: a laser light source having a wavelength from 380 nm to 490 nm; and a beam guidance element, the laser light source configured for generating an average surface power density of more than 10 W/cm2, the beam guidance element including a glass which has a quality factor F(436 nm)=S(436 nm)*(Abs0(436 nm)+Abs1(436 nm))/k, wherein S(436 nm) is a thermality at a wavelength of 436 nm, Abs1(436 nm) is an additional absorbance in comparison to Abs0(436 nm) at a wavelength of 436 nm after an irradiation with a power density of 345 W/cm2 for 72 hours with a laser light having a wavelength of 455 nm, Abs0(436 nm) is an absorbance at a wavelength of 436 nm of a sample having a thickness of 100 mm without the irradiation, k is the thermal conductivity, and the quality factor F(436 nm) is
Abstract:
A method for producing a glass article having high hydrolytic resistance is provided. A glass tube consisting of borosilicate glass and having an Al2O3 content of less than 1 weight-%, a ZrO2 content of 2-12 weight-%, and a glass transition temperature Tg is reshaped into a glass article and is subsequently subjected to a thermal post-treatment. To reduce the alkali release of the glass article, the glass article is subjected to a treatment temperature of TB≥Tg+5° K over a treatment time of tB≥5 min and is subsequently cooled during the thermal post-treatment.
Abstract:
A method for producing a glass article having high hydrolytic resistance is provided. A glass tube consisting of borosilicate glass and having an Al2O3 content of less than 1 weight-%, a ZrO2 content of 2-12 weight-%, and a glass transition temperature Tg is reshaped into a glass article and is subsequently subjected to a thermal post-treatment. To reduce the alkali release of the glass article, the glass article is subjected to a treatment temperature of TB≥Tg+5° K over a treatment time of tB≥5 min and is subsequently cooled during the thermal post-treatment.
Abstract:
A pharmaceutical packaging is provided including a glass, comprising at least the following components (given in mol % on oxide basis): SiO2:59-84, Al2O3:7-18.5, CaO:1-25, SrO:0-6.5, BaO:0-5, ZrO2:0-3, TiO2:0-5, B2O3:0-1, wherein the ratio (CaO+SrO+BaO)/Al2O3